New hope for kids with CF: triple therapy shows promise in young patients
Disease control
Completed
This study looked at how well a triple combination therapy (elexacaftor, tezacaftor, and ivacaftor, or ETI) works in children aged 6 to 11 with cystic fibrosis (CF) who have a specific genetic mutation. Researchers measured changes in sweat chloride, lung function, and growth ove…
Sponsor: Nicole Hamblett • Aim: Disease control
Last updated May 14, 2026 12:05 UTC